## Byeong-zu Ghang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1093363/publications.pdf

Version: 2024-02-01

933447 996975 23 273 10 15 citations g-index h-index papers 27 27 27 602 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2018, 48, 462-466.	3.4	30
2	CD14+ Cells with the Phenotype of Infiltrated Monocytes Consist of Distinct Populations Characterized by Anti-inflammatory as well as Pro-inflammatory Activity in Gouty Arthritis. Frontiers in Immunology, 2017, 8, 1260.	4.8	24
3	Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin. American Journal of Medicine, 2017, 130, 583-587.	1.5	23
4	Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Modern Rheumatology, 2017, 27, 405-410.	1.8	23
5	Longterm Outcomes of Renal Artery Involvement in Takayasu Arteritis. Journal of Rheumatology, 2017, 44, 466-472.	2.0	18
6	IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model. Frontiers in Immunology, 2018, 9, 1544.	4.8	18
7	Surgical Outcomes in Behcet's Disease Patients With Severe Aortic Regurgitation. Annals of Thoracic Surgery, 2019, 107, 1188-1194.	1.3	15
8	Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 275.	3 <b>.</b> 5	15
9	Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 155, 43-48.	2.9	14
10	Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes. Clinical and Experimental Rheumatology, 2016, 34, S77-83.	0.8	13
11	Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis. International Journal of Molecular Sciences, 2019, 20, 2606.	4.1	12
12	Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. Korean Journal of Internal Medicine, 2019, 34, 442-451.	1.7	11
13	Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial. Rheumatology, 2020, 59, 1439-1440.	1.9	10
14	Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea. Korean Journal of Internal Medicine, 2017, 32, 1090-1097.	1.7	9
15	Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open, 2022, 8, e001944.	3.8	9
16	Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting. Seminars in Arthritis and Rheumatism, 2021, 51, 685-691.	3.4	8
17	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses, 2021, 13, 329.	3.3	4
18	Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients. Clinical Rheumatology, 2021, 40, 2447-2456.	2.2	4

#	Article	IF	CITATIONS
19	Clinical features and risk of recurrence of acute calcium pyrophosphate crystal arthritis. Clinical and Experimental Rheumatology, 2019, 37, 254-259.	0.8	3
20	Expression of Inflammatory Markers in the Muscles of Patients with Idiopathic Inflammatory Myopathy According to the Presence of Interstitial Lung Disease. Journal of Clinical Medicine, 2022, 11, 3021.	2.4	1
21	The Reply. American Journal of Medicine, 2017, 130, e469.	1.5	0
22	Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine. Journal of Rheumatic Diseases, 2022, 29, 56-57.	1.1	0
23	Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents. Clinical and Experimental Rheumatology, 2018, 36, 170.	0.8	0